---
title: "BUZZ-Bristol Myers drops after Reuters reports no ongoing AstraZeneca deal talks"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294966486.md"
datetime: "2026-08-05T12:21:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294966486.md)
  - [en](https://longbridge.com/en/news/294966486.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294966486.md)
generator: "portal-rs"
---

# BUZZ-Bristol Myers drops after Reuters reports no ongoing AstraZeneca deal talks

Shares of Bristol Myers Squibb (BMY.N) fall 2.2% to $64.46 premarket There are “no discussions” ongoing between AstraZeneca (AZN.L) and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters

“There is no deal between AstraZeneca and BMS. There never was a deal to be done, and there are no discussions between the companies,” said the source Reuters had earlier reported that initial discussions had taken place, but it was unclear whether talks were still ongoing

U.S.-listed shares of AstraZeneca (AZN.N) jumped 5.8% before the bell

As of last close, BMY up 22.2% YTD

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Cramer's lightning round: 'I am not going to put my money on AstraZeneca'](https://longbridge.com/en/news/298373941.md)
- [Bristol Myers Swoons on Test Results](https://longbridge.com/en/news/298335284.md)
- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)
- [Health Rounds: AstraZeneca drug reduces lung disease flare-ups in late-stage trials](https://longbridge.com/en/news/298355260.md)
- [Bristol Myers' blood cancer cell therapy meets main goal in mid-stage trial](https://longbridge.com/en/news/298308696.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**